Balchem Posts Record 2025 Results as Q4 Sales and Earnings Climb

Overview

• Fourth-quarter net sales reached $263.6 million, up 9.8% year over year, with net earnings of $39.2 million rising 16.8%.
• Full-year 2025 finished at $1.037 billion in revenue, $154.8 million in net earnings, and $173.6 million in free cash flow, all record levels.
• Adjusted EBITDA increased to $67.9 million in Q4 and $274.9 million for the year, reflecting a 9.8% annual improvement.
• Human Nutrition and Health led Q4 with $166.1 million in sales and double-digit growth, as Animal Nutrition and Specialty Products also advanced.
• The company ended 2025 with $74.6 million in cash, $164 million in revolver borrowings, net debt of $89.4 million, leverage of 0.3x, a higher dividend, and shares down 1.41% on the release to $175.00.